Most Read

Branaplam has been demonstrated to decrease levels of mutant huntingtin protein in preclinical models, said Novartis. Based on the results, Novartis aims to begin a development programme for

NantKwest and ImmunityBio’s hAd5-Covid-19 is a novel Covid-19 vaccine candidate designed to target the inner nucleocapsid (N) and the outer spike (S) protein, as well as activate both

PMM is a complex mitochondrial disease in which genetic mutations mainly impair the function of mitochondria that may result in reduced muscle function, reduced endurance to exercise, increased

With a combined area of 8,700m² in the Stellar 32 campus within Geneva’s ZIPLO, the newly expanded facility will co-locate primary European operations of both companies. KBI Biopharma’s

In May 2018, Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) entered into an initial agreement to develop and commercialise Korsuva to treat CKD-aP in haemodialysis

The approval from an Indian regulator allows conducting an adaptive phase 2/3 human clinical trial for Sputnik V vaccine in the country. According to RDIF, the multi-centre and

The deal also allows Disarm equity-holders to secure up to $1.225bn in additional future payments for potential development, regulatory and commercial milestones based on the successful development and

The human adenovirus (hAd5) vector vaccine candidate has been designed to target both the inner nucleocapsid (N) and outer spike (S) proteins, said ImmunityBio. The N-protein has been

Inmazeb, which was previously called REGN-EB3, is now the first treatment to have been approved by the FDA for Ebola. The antibody cocktail has been indicated for the